Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.74 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092280 | 0.85 | MET (1.00) | METNQO2 | |
| SCHEMBL3089413 | 0.83 | MET (0.85) | METNQO2 | |
| SCHEMBL1581596 | 0.83 | MET (0.73) | METNQO2 | |
| SCHEMBL3101965 | 0.83 | MET (0.87) | METNQO2 | |
| SCHEMBL3088090 | 0.82 | MET (0.81) | METNQO2 | |
| SCHEMBL1581481 | 0.81 | MET (0.72) | METNQO2 | |
| SCHEMBL1317047 | 0.81 | MET (0.70) | METNQO2 | |
| SCHEMBL3102320 | 0.81 | MET (0.81) | METNQO2 | |
| SCHEMBL3087171 | 0.81 | MET (1.00) | METNQO2 | |
| SCHEMBL3090717 | 0.81 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376426-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-06-28 | — | — | US | claimed |
| US-20140148463-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148463-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 598/4885ROCK2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.